ArticleInternational journal of general medicine2025
Association of the Neutrophil Percentage-to-Albumin Ratio with All-Cause Mortality in Patients with Hypercapnic Respiratory Failure: A Prospective Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The neutrophil percentage-to-albumin ratio (NPAR) has emerged as a widely used inflammatory marker for predicting clinical outcomes across various diseases; however, its prognostic value in hypercapnic respiratory failure (HRF) remains uncertain. This study aimed to examine the association between NPAR and all-cause mortality in patients with HRF. Methods: This prospective cohort study enrolled 561 HRF patients hospitalized at Yancheng First People's Hospital between October 2020 and September 2021. The primary outcome was 24-month all-cause mortality; secondary outcomes included mortality at 3, 6, and 12 months. The association between NPAR and all-cause mortality was assessed using restricted cubic spline (RCS) modeling, multivariate Cox proportional hazards models, Kaplan-Meier survival analysis, and subgroup analyses. Discriminatory performance was evaluated using the area under the receiver operating characteristic curve (AUC). Results: RCS modeling demonstrated a significant linear association between NPAR and all-cause mortality in HRF patients (P for overall association < 0.001). Both the Cox models and Kaplan-Meier analyses indicated that elevated NPAR levels were significantly associated with increased 3-, 6-, 12-, and 24-month all-cause mortality (all P < 0.05). Subgroup analysis further supported an independent association between NPAR and mortality. The AUC for NPAR in predicting 12-month all-cause mortality was 0.66 (95% confidence interval [CI], 0.61-0.71), which was significantly higher than that of neutrophil percentage or albumin alone (AUC =0.62; 95% CI, 0.57-0.67; P < 0.05). Conclusion: Elevated NPAR is independently associated with increased all-cause mortality in patients with HRF. As a composite marker reflecting both systemic inflammation and nutritional status, NPAR may serve as a robust prognostic indicator to enhance risk stratification and guide clinical decision-making in HRF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.